参考文献
[1] LEHMANN B D, BAUER J A, CHEN X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies [J]. The Journal of clinical investigation, 2011, 121(7): 2750-67.
[2] SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer [J]. The New England journal of medicine, 2018, 379(22): 2108-21.
[3] MILES D, GLIGOROV J, ANDR F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer [J]. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, 32(8): 994-1004.
[4] SCHMID P, CORTES J, PUSZTAI L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer [J]. The New England journal of medicine, 2020, 382(9): 810-21.
[5] FDA. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. (2021-07-27)[2023-07-27]. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer | FDA
[6] CORTES J, RUGO H S, CESCON D W, et al. 2022. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med [J], 387: 217-226.
[7] CORTES J, CESCON D W, RUGO H S, et al. 2020. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet [J], 396: 1817-1828.
[8] JIANG Z F, OUYANG Q C, SUN T, et al. TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). J Clin Oncol 41, 2023 (suppl 17; abstr LBA1013)[2023-07-27]. Program Guide – ASCO Meeting Program Guide. DOI:10.1200/JCO.2023.41.17_suppl.LBA1013
[9] 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2022年版）[J]. 国际肿瘤学杂志, 2022, 49(11): 641-657.
[10] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 (CSCO) 食管癌诊疗指南2023[M]. 北京: 人民卫生出版社, 2023: 70.
[11] 孙春晓, 王树森, 李健斌, 等. 紫杉醇脂质体在晚期乳腺癌中应用的真实世界研究 [J] . 中华肿瘤杂志, 2023, 45(1) : 88-94.